{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:05:50Z","timestamp":1785161150069,"version":"3.55.0"},"reference-count":169,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the ATHENA Institute of Biomedical Sciences and the EnergonBio Technologies S.A., Greece","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Until more data are available to shed light on the thyroid disorders related to immune checkpoint inhibitors (ICPi) implemented for the treatment of hematological malignancies, the decision-making is guided by pertinent data derived mostly from solid tumors. Methods: The present review provides a comprehensive and updated overview of the thyroid disorders related to ICPi, namely to inhibitors of cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death (PD) 1 (PD-1), and the ligand of the latter (PD-L1). Results: With the increasing recognition of ir thyroid disorders, many outstanding issues have emerged. Ir thyroid disorders are reminiscent of, but not identical to, thyroid autoimmunity. Interclass and intraclass ICPi differences regarding thyroid immunotoxicity await interpretation. The available data concerning the predictive value of thyroid autoantibodies for the development of ir thyroid disorders are inconclusive. Mounting data indicate an association of ir thyroid disorders with ICPi efficacy, but a causative link is still lacking. The path forward is a tailored approach, entailing: (i) the validation of tumor-specific, patient-specific, and ICPi-specific predictive factors; (ii) appropriate patient selection; (iii) the uncoupling of antitumor immunity from immunotoxicity; (iv) a multidisciplinary initiative; and (v) global registry strategies. Conclusions: Untangling and harnessing the interrelationship of immuno-oncology with endocrinology underlying the ir thyroid disorders will yield the optimal patient care.<\/jats:p>","DOI":"10.3390\/cancers13215277","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T14:37:48Z","timestamp":1634827068000},"page":"5277","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries"],"prefix":"10.3390","volume":"13","author":[{"given":"Maria V.","family":"Deligiorgi","sequence":"first","affiliation":[{"name":"Department of Pharmacology\u2014Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, Building 16, 1st Floor, 75 Mikras Asias Str., Goudi, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-7947","authenticated-orcid":false,"given":"Sofia","family":"Sagredou","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2014Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, Building 16, 1st Floor, 75 Mikras Asias Str., Goudi, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-3035","authenticated-orcid":false,"given":"Lampros","family":"Vakkas","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2014Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, Building 16, 1st Floor, 75 Mikras Asias Str., Goudi, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-9780","authenticated-orcid":false,"given":"Dimitrios T.","family":"Trafalis","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2014Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, Building 16, 1st Floor, 75 Mikras Asias Str., Goudi, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: A review","volume":"21","author":"Hattersley","year":"2021","journal-title":"Clin. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/sci.2017.03.04","article-title":"Immune checkpoint blockade for hematologic malignancies: A review","volume":"4","author":"Pianko","year":"2017","journal-title":"Stem Cell Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-020-00947-6","article-title":"Targeting immune checkpoints in hematological malignancies","volume":"13","author":"Salik","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/phar.2035","article-title":"Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies","volume":"37","author":"Ali","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System","volume":"14","author":"Raschi","year":"2019","journal-title":"Target Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS","volume":"9","author":"Ji","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur. Thyroid J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3803\/EnM.2019.34.1.29","article-title":"Graves\u2019 Disease: Can It Be Cured?","volume":"34","author":"Wiersinga","year":"2019","journal-title":"Endocrinol. Metab."},{"key":"ref_10","unstructured":"(2021, March 25). Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"282147","DOI":"10.1155\/2014\/282147","article-title":"Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells","volume":"2014","author":"Orio","year":"2014","journal-title":"Sci. World J."},{"key":"ref_12","unstructured":"Gardner, D., and Shoback, D. (2011). Chapter 7. The Thyroid Gland. Greenspan\u2019s Basic and Clinical Endocrinology, McGraw-Hill Education\u2014Europe. [9th ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fendo.2019.00059","article-title":"Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies","volume":"10","author":"Krashin","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: Pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.isci.2020.101580","article-title":"Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade","volume":"23","author":"Hu","year":"2020","journal-title":"IScience"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1089\/thy.2017.0062","article-title":"Anti-PD-1 Antibody Therapy Induces Hashimoto\u2019s Disease with an Increase in Peripheral Blood Follicular Helper T Cells","volume":"27","author":"Torimoto","year":"2017","journal-title":"Thyroid"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1089\/thy.2018.0418","article-title":"Histology of Nivolumab-Induced Thyroiditis","volume":"28","author":"Neppl","year":"2018","journal-title":"Thyroid"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","article-title":"The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy","volume":"6","author":"Young","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e201611","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/DDDT.S196316","article-title":"Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: A comprehensive systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"51","author":"Andreescu","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","volume":"4","author":"Barry","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.intimp.2018.08.014","article-title":"Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials","volume":"63","author":"Zhang","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1\/PD-L1 Inhibitors in Cancer Patients","volume":"5","author":"Je","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: A meta-analysis","volume":"12","author":"ElHalawani","year":"2016","journal-title":"Future Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"10","author":"Da","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review","volume":"9","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1089\/thy.2020.0032","article-title":"Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: A scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ferrari, S.M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M.R., Baldini, E., Ulisse, S., and Marone, G. (2019). Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102560"},{"key":"ref_42","first-page":"119","article-title":"Checkpoint Inhibitors","volume":"116","author":"Heinzerling","year":"2019","journal-title":"Dtsch Arztebl Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-19-0535","article-title":"Immune checkpoint inhibitor-associated thyroid dysfunction: A disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase","volume":"182","author":"Bai","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19419","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: A retrospective analysis of the French Pharmacovigilance database","volume":"9","author":"Petitpain","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"SAT-418","DOI":"10.1210\/jendso\/bvaa046.127","article-title":"SAT-418 Finding the Needles in the Haystack: Harnessing the Electronic Health Record to Find Thyroid Immune Related Adverse Events","volume":"4","author":"Quandt","year":"2020","journal-title":"J. Endocr. Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e000371","DOI":"10.1136\/jitc-2019-000371","article-title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","volume":"8","author":"Nuzzo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1701337","article-title":"Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults","volume":"22","author":"Kauppila","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4274\/jcrpe.v3i2.18","article-title":"Thyroid functions in long-term survivors of pediatric Hodgkin\u2019s lymphoma treated with chemotherapy and radiotherapy","volume":"3","author":"Demirkaya","year":"2011","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/mpo.2950090505","article-title":"Cyclical combination chemotherapy and thyroid function in patients with advanced Hodgkin\u2019s disease","volume":"9","author":"Sutcliffe","year":"1981","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000464285","article-title":"Tremelimumab-Induced Graves Hyperthyroidism","volume":"6","author":"Gan","year":"2017","journal-title":"Eur. Thyroid J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4158\/EP171832.OR","article-title":"Rapid evolution of thyroid dysfunction in patients treated with nivolumab","volume":"23","author":"Lee","year":"2017","journal-title":"Endocr. Pract."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-Related Thyroiditis with Immune Checkpoint Inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fidilio, E., Navarro-Gonz\u00e1lez, E., Romero-Lluch, A.R., Iglesias, P., Diez G\u00f3mez, J.J., Anda Api\u00f1\u00e1niz, E., Santos Mazo, E., and Zaf\u00f3n, C. (2020). Thyroid disorders associated with immune control point inhibitors. Endocrinol. Diabetes Nutri.","DOI":"10.1016\/j.endien.2021.10.004"},{"key":"ref_61","unstructured":"Dermott, M.T. (2013). Hypothyroidism in Endocrine secrets, Elsevier Saunders. [6th ed.]."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Giammanco, M., Di Liegro, C.M., Schiera, G., and Di Liegro, I. (2020). Genomic and Non-Genomic Mechanisms of Action of Thyroid Hormones and Their Catabolite 3,5-Diiodo-L-Thyronine in Mammals. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114140"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IOP.0000000000001161","article-title":"Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/IOP.0000000000000033","article-title":"Ipilimumab-induced orbital inflammation resembling graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression","volume":"30","author":"Borodic","year":"2014","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/IOP.0b013e3182895795","article-title":"Re: \"Drug-induced Graves disease from CTLA-4 receptor suppression\"","volume":"29","author":"Sohrab","year":"2013","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000485742","article-title":"Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment","volume":"7","author":"Campredon","year":"2018","journal-title":"Eur. Thyroid J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/1078155219835912","article-title":"Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy","volume":"26","author":"Johnson","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_71","first-page":"140092","article-title":"A novel melanoma therapy stirs up a storm: Ipilimumab-induced thyrotoxicosis","volume":"2015","author":"Yu","year":"2015","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13256-018-1708-x","article-title":"Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto\u2019s disease and diabetes mellitus: A case report","volume":"12","author":"Yonezaki","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"ref_73","first-page":"10","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gummalla, S., Manjunath, M., and Phillips, B. (2020). \u201cMyxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab\u201d. Case Rep. Endocrinol., 2020.","DOI":"10.1155\/2020\/8855943"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","author":"Khan","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2020.02.025","article-title":"Emergency presentations in patients treated with immune checkpoint inhibitors","volume":"130","author":"Cooksley","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/emp2.12209","article-title":"Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department","volume":"1","author":"Yeung","year":"2020","journal-title":"J. Am. Coll. Emerg. Physicians Open"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4158\/EP.17.3.456","article-title":"American Thyroid Association, & American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"17","author":"Bahn","year":"2011","journal-title":"Endocr. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National Comprehensive Cancer Network Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2213-8587(15)00225-9","article-title":"Thyroid function in critically ill patients","volume":"3","author":"Fliers","year":"2015","journal-title":"lancet Diabetes Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/RLU.0000000000000726","article-title":"Effect of recent contrast-enhanced CT and patient age on image quality of thyroid scintigraphy","volume":"40","author":"Andersen","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_83","first-page":"113","article-title":"Nuclear medicine in the diagnosis of benign thyroid diseases","volume":"15","year":"2012","journal-title":"Nucl. Med. Rev. Cent. East. Eur."},{"key":"ref_84","first-page":"204","article-title":"Transient thyrotoxicosis during nivolumab treatment","volume":"75","author":"Glaudemans","year":"2017","journal-title":"Neth. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MNM.0b013e328324b431","article-title":"Evaluation of thyroid FDG uptake incidentally identified on FDG-PET\/CT imaging","volume":"30","author":"Chen","year":"2009","journal-title":"Nucl. Med. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00006231-200402000-00004","article-title":"Elevated 18F-FDG uptake in skeletal muscles and thymus: A clue for the diagnosis of Graves\u2019 disease","volume":"25","author":"Chen","year":"2004","journal-title":"Nucl. Med. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Yamauchi, I., Yasoda, A., Matsumoto, S., Sakamori, Y., Kim, Y.H., Nomura, M., Otsuka, A., Yamasaki, T., Saito, R., and Kitamura, M. (2019). Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216954"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0042-119528","article-title":"Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms","volume":"125","author":"Alhusseini","year":"2017","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_90","unstructured":"(2019, July 24). Management of immunotherpy-Related Toxicities. National Comphrehensive Cancer Network (NCCN) Guidelines. Version 2. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13256-019-2002-2","article-title":"Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: A case report and review of the literature","volume":"13","author":"Ohara","year":"2019","journal-title":"J. Med. Case Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jjco\/hyw036","article-title":"Nivolumab-induced thyroid dysfunction","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_96","first-page":"1035","article-title":"Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer","volume":"31","author":"Maekura","year":"2017","journal-title":"In Vivo"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J. Endocr. Soc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Matsuoka, H., Hayashi, T., Takigami, K., Imaizumi, K., Shiroki, R., Ohmiya, N., Sugiura, K., Kawada, K., Sawaki, A., and Maeda, K. (2020). Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07142-3"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Yano, S., Ashida, K., Nagata, H., Ohe, K., Wada, N., Takeichi, Y., Hanada, Y., Ibayashi, Y., Wang, L., and Sakamoto, S. (2018). Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma. BMC Endocr. Disord., 18.","DOI":"10.1186\/s12902-018-0267-x"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1530\/EC-19-0473","article-title":"Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction","volume":"9","author":"Lord","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.autrev.2012.07.003","article-title":"TSH receptor autoantibody immunoassay in patients with Graves\u2019 disease: Improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis","volume":"12","author":"Tozzoli","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/cen.13327","article-title":"Measuring TSH receptor antibody to influence treatment choices in Graves\u2019 disease","volume":"86","author":"Abraham","year":"2017","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/thy.2016.0017","article-title":"Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves\u2019 Disease Relapse","volume":"26","author":"Tun","year":"2016","journal-title":"Thyroid"},{"key":"ref_109","first-page":"2087525","article-title":"Case Report Treatment of Ipilimumab Induced Graves \u2018 Disease in a Patient with Metastatic Melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep. Endocrinol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3389\/fendo.2018.00813","article-title":"Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis","volume":"17","author":"Iadarola","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000501824","article-title":"Graves\u2019 Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature","volume":"8","author":"Brancatella","year":"2019","journal-title":"Eur. Thyroid J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaapos.2018.01.006","article-title":"A case of Graves\u2019 ophthalmopathy associated with pembrolizumab (Keytruda) therapy","volume":"22","author":"Park","year":"2018","journal-title":"J. AAPOS"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jdi.13212","article-title":"Simultaneous development of Graves\u2019 disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report","volume":"11","author":"Kurihara","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Yamada, H., Okajima, F., Onda, T., Fujimori, S., Emoto, N., and Sugihara, H. (2020). New-onset graves\u2019 disease after the initiation of nivolumab therapy for gastric cancer: A case report. BMC Endocr. Disord., 20.","DOI":"10.1186\/s12902-020-00613-5"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Xu, H., Xu, X., Ge, W., Lei, J., and Cao, D. (2020). The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: A systematic review and meta-analysis. Ther. Adv. Med. Oncol., 12.","DOI":"10.1177\/1758835920980546"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., and Zhang, F. (2020). Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med., 18.","DOI":"10.1186\/s12916-020-01549-2"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J. Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.clgc.2020.07.003","article-title":"Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review","volume":"19","author":"Kijima","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Haratani, K., Hayashi, H., and Nakagawa, K. (2020). Association of immune-related adverse events with immune checkpoint inhibitor efficacy: Real or imaginary?. BMC Med, 18.","DOI":"10.1186\/s12916-020-01583-0"},{"key":"ref_121","first-page":"2140","article-title":"Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade","volume":"18","author":"Sakakida","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","article-title":"Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients","volume":"48","author":"Campredon","year":"2019","journal-title":"Presse Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10637-017-0534-0","article-title":"Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience","volume":"36","author":"Fujii","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"649863","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: Update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3389\/fendo.2019.00772","article-title":"Stem Cells, Self-Renewal, and Lineage Commitment in the Endocrine System","volume":"10","author":"Mariniello","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4103\/2230-8210.117248","article-title":"Endocrine complications after busulphan and cyclophosphamide based hematopoietic stem cell transplant: A single tertiary care centre experience","volume":"17","author":"Gundgurthi","year":"2013","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e14049","DOI":"10.1111\/ctr.14049","article-title":"Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation","volume":"34","author":"Akkus","year":"2020","journal-title":"Clin. Transplant."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/0748730415580881","article-title":"Clocks within the Master Gland: Hypophyseal Rhythms and Their Physiological Significance","volume":"30","author":"Lin","year":"2015","journal-title":"J. Biol. Rhythms"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00702-020-02260-5","article-title":"Hypothyroidism after radiation exposure: Brief narrative review","volume":"127","author":"Reiners","year":"2020","journal-title":"J. Neural Transm.(Vienna)"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-014-0162-0","article-title":"Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Vantyghem","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2012.42.3038","article-title":"Delivering care to long-term adult survivors of hematopoietic cell transplantation","volume":"30","author":"Syrjala","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1515\/jpem-2018-0020","article-title":"Long-term thyroid disorders in pediatric survivors of hematopoietic stem cell transplantation after chemotherapy-only conditioning","volume":"31","author":"Cima","year":"2018","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000517175","article-title":"European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction","volume":"10","author":"Bednarczuka","year":"2021","journal-title":"Eur. Thyroid J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-up of the Multicohort Single-Arm Phase Ii Checkmate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for Classical Hodgkin\u2019s Lymphoma after Failure of Both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/blood-2018-99-112067","article-title":"Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (Chl) after Autologous Hematopoietic Cell Transplantation (Auto-HCT): Extended Follow-up of the Phase 2 Single-Arm Checkmate 205 Study","volume":"132","author":"Armand","year":"2018","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase Ii Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood-2018-99-117045","article-title":"Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"132","author":"Zinzani","year":"2018","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2019-123906","article-title":"Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD","volume":"134","author":"Allen","year":"2019","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumor- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4081\/oncol.2020.490","article-title":"Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm","volume":"14","author":"Banna","year":"2020","journal-title":"Oncol. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2019.01.015","article-title":"Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology","volume":"112","author":"Heinzerling","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s40425-019-0799-2","article-title":"Peripheral immune-based biomarkers in cancer immunotherapy: Can we realize their predictive potential?","volume":"7","author":"Nixon","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1346-8138.13028","article-title":"Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab","volume":"43","author":"Narita","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Madama, D., and Pego, A. (2020). Are patients with autoimmune disorders eligible for immunotherapy?. Pulmonology, Advance online publication.","DOI":"10.1016\/j.pulmoe.2020.04.019"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/1759-7714.13057","article-title":"Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer","volume":"10","author":"Kuo","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40425-016-0148-7","article-title":"Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma","volume":"4","author":"Amin","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/bjc.2017.145","article-title":"A Phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)","volume":"117","author":"Weiss","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A Phase I dose-escalation trial","volume":"13","author":"Versluis","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for Patients with Relapse after Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2017.35.15_suppl.7519","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40618-020-01276-8","article-title":"COVID-19 and the endocrine system: Exploring the unexplored","volume":"43","author":"Pal","year":"2020","journal-title":"J. Endocrinol. Investig."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:19:59Z","timestamp":1760167199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":169,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13215277"],"URL":"https:\/\/doi.org\/10.3390\/cancers13215277","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}